Overview

Efficacy Study of Metformin Glycinate on Postprandial Lipemia

Status:
Unknown status
Trial end date:
2020-08-01
Target enrollment:
Participant gender:
Summary
The aim of this study is to evaluate the effect of metformin glycinate vs metformin hydrochloride on postprandial lipemia. 72 patients will be included, they will be randomized and assigned into one of the two treatment groups: metformin glycinate 1240 mg BID or metformin hydrochloride 1000 mg BID (36 patients per group). The patients will be followed for 4 months. Blood count, blood chemistry, liver profile, lipid profile, HbA1c, apolipoprotein B, oxidized LDL, fibroblast growth factor 21, leptin, adiponectin, C-reactive protein, free fatty acids, fibrinogen, Goodpasture Binding Protein (GPBP) and antioxidant activity of plasma will be measured at baseline and 4 months. Additionally, after a structured meal, the following parameters will be measured: glucose, insulin, triglycerides, apolipoprotein B and oxidized LDL. (baseline and 4 months). Throughout the study adverse events will be documented.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Laboratorios Silanes S.A. de C.V.
Collaborator:
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Treatments:
Metformin